<DOC>
	<DOC>NCT02093273</DOC>
	<brief_summary>The objective of this study is to compare the antibody response 30 days after two doses of t OPV</brief_summary>
	<brief_title>Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)</brief_title>
	<detailed_description>The trial design is phase II, randomized, double blind, prospective intervention study. The subject study are 240 healthy, full term, newborn infants.</detailed_description>
	<criteria>Healthy, full term, newborns infants newborn residing within a relatively short and easily accessible distance A(&lt;30km) from the study clinic(s) and not planning to travel away during the entire study period Infant born after 37 weeks of pregnancy Infant weighing 2.5kg or more at birth (birth weight &gt;= 2.5kg) Healthy newborns, with no history of asphyxia or meconium aspiration Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form. Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial Mother at least elementary school graduate Child concomitantly enrolled or scheduled to be enrolled in another trial Known history of congenital or acquired immunodeficiency (including HIV infection) Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature &gt;=37.5oC Newborns requiring hospitalization at birth Infant immunized with nonscheduled OPV or IPV during trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>tOPV</keyword>
	<keyword>Antibody response</keyword>
	<keyword>Safety</keyword>
</DOC>